Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: A pilot study

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 16, 2008, Pages 2741-2750

  Florentin, M ^a   Liberopoulos, E N ^a   Filippatos, T D ^a   Kostara, C ^a   Tselepis, A ^b   Mikhailidis, D P ^c   Elisaf, M ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Body weight; Fenofibrate; High density lipoprotein cholesterol; Rimonabant; Triglycerides; Waist circumference

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; RIMONABANT; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DYSLIPIDEMIA; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; LOW CALORY DIET; MALE; MENTAL DISEASE; METABOLIC DISORDER; MONOTHERAPY; MOOD DISORDER; NAUSEA; OBESITY; PATIENT COMPLIANCE; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; CARDIOVASCULAR SYSTEM; FEMALE; HEART; HUMANS; MALE; MIDDLE AGED; OVERWEIGHT; PILOT PROJECTS; PIPERIDINES; PROCETOFEN; PYRAZOLES; RISK FACTORS; TIME FACTORS; WAIST CIRCUMFERENCE;

EID: 56749138548     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.16.2741     Document Type: Article

References (34)

1. Solomon CG, Manson JE. Obesity and mortality: a review of the epidemiologic data. Am J Clin Nutr 1997;66:S1044-50
2. Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004;110:2952-67
3. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004;89:2583-9
4. Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 2005;294:1773-81
5. Liberopoulos EN, Mikhailidis DP, Elisaf MS. Diagnosis and management of the metabolic syndrome in obesity. Obes Rev 2005;283-96
6. Liberopoulos EN, Tsouli S, Mikhailidis DP, Elisaf MS. Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets 2006;7:211-28
7. Wadden TA, Butryn ML. Behavioral treatment of obesity. Endocrinol Metab Clin North Am 2003;32:981-1003
8. Kiortsis DN, Filippatos TD, Elisaf MS. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 2005; 31:15-22
9. Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005;21:457-68
10. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007;369:71-7
11. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97
12. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-34
13. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-75
14. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006;368:1660-72
15. Van Gaal L, Pi-Sunyer X, Despres JP, et al. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 2008;31 (Suppl 2):S229-40
16. Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart 2008;94:706-14
17. Tsimihodimos V, Miltiadous G, Daskalopoulou SS, et al. Fenofibrate: metabolic and pleiotropic effects. Curr Vasc Pharmacol 2005;3:87-98
18. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
19. Noakes M, Keogh JB, Foster PR, Clifton PM. Effect of an energy-restricted, high-protein, low-fat diet relative to a conventional high-carbohydrate, low-fat diet on weight loss, body composition, nutritional status, and markers of cardiovascular health in obese women. Am J Clin Nutr 2005;81:1298-306
20. Sartorio A, Lafortuna CL, Vangeli V, et al. Short-term changes of cardiovascular risk factors after a non-pharmacological body weight reduction program. Eur J Clin Nutr 2001;55:865-9
21. Nakou ES, Filippatos TD, Georgoula M, et al. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin 2008;24:1919-29
22. Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 2005;21:1997-2006
23. Brinton EA, Eisenberg S, Breslow JL. A low-fat diet decreases high density lipoprotein (HDL) cholesterol levels by decreasing HDL apolipoprotein transport rates. J Clin Invest 1990;85:144-51
24. Brinkworth GD, Wycherley TP, Noakes M, Clifton PM. Reductions in blood pressure following energy restriction for weight loss do not rebound after re-establishment of energy balance in overweight and obese subjects. Clin Exp Hypertens 2008;30:385-96
25. Kastelein JJ, van der Steeg WA, Holme I, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008;117:3002-9
26. Gazi IF, Tsimihodimos V, Tselepis AD, et al. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 2007;7:53-72
27. Chan DC, Barrett PH, Watts GF. Lipoprotein transport in the metabolic syndrome: pathophysiological and interventional studies employing stable isotopy and modelling methods. Clin Sci Lond 2004;107:233-49
28. Chan DC, Barrett PH, Watts GF. Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders. Curr Opin Lipidol 2006;17:28-36
29. Watts GF, Barrett PH, Ji J, et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 2003;52:803-11
30. Watts GF, Ji J, Chan DC, et al. Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome. Clin Sci Lond 2006;111:193-9
31. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008;23:370-8
32. McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008;372:224-33
33. Serrano A, Del Arco I, Javier Pavon F, et al. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats. Neuropharmacology 2008;54:226-34
34. Daskalopoulou SS, Mikhailidis DP, Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology 2004;55:589-612